Zerbaxa is owned by Cubist Pharms Llc.

Zerbaxa contains Ceftolozane Sulfate; Tazobactam Sodium.

Zerbaxa has a total of 14 drug patents out of which 0 drug patents have expired.

Zerbaxa was authorised for market use on 19 December, 2014.

Zerbaxa is available in powder;intravenous dosage forms.

Zerbaxa can be used as treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia, treatment of hospital-acquired bacterial pneumonia; treatment of ventilator-associated bacterial pneumonia, methods of treating bacterial illnesses; methods for treating bacterial infections, treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection, treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis, methods of treating bacterial illnesses, treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis, treatment of hospital-acquired bacterial pneumonia (habp); treatment of ventilator-associated bacterial pneumonia (vabp), treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection.

Drug patent challenges can be filed against Zerbaxa from 2023-12-20.

The generics of Zerbaxa are possible to be released after 14 August, 2035.